AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02483663 — intervention group
Intervention type: OTHER
Intervention: Test Meals
Description: Breakfast, a snack, and lunch provided during study visit.
Study NCT02483663 — intervention group
Intervention type: OTHER
Intervention: Computer Tests
Description: Perform a series of computer tests to determine reaction time.
Study NCT02483663 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous Catheter (IV) placement
Description: Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
Study NCT03209102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical assessment
Description: * Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)~* and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning
Study NCT03209102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress elicitation experiment
Description: The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.~During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect).
Study NCT03209102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural and Functional MRI
Description: Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.~For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome.
Study NCT03209102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: salivary collections of amylase and cortisol
Description: Collection of saliva samples of cortisol and amylase repeated three times
Study NCT04075474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: 38% SDF on primary upper anterior teeth
Study NCT04075474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sodium fluoride
Description: 5% NaF on primary upper anterior teeth
Study NCT02192203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac + Menthol Gel
Description: 1% diclofenac, 3% menthol
Study NCT02192203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Only Gel
Description: 1% diclofenac, 0.09% menthol
Study NCT02192203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Only Gel
Description: 3% menthol
Study NCT02192203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Only Gel
Description: 0.09% menthol
Study NCT04032600 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Paracentesis
Description: Full versus partial paracentesis (3 liters)
Study NCT01709149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-2017357
Description: CK-2017357 125 mg tablets twice daily
Study NCT01709149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Tablets
Study NCT01709149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Tablets
Study NCT01709149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: Tablets
Study NCT03201458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03201458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT03201458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03201458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT03201458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03201458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00576459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.59 mg fluocinolone acetonide intravitreal implant
Description: 0.59 mg
Study NCT00576459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.1 mg fluocinolone acetonide intravitreal implant
Description: 2.1 mg
Study NCT00576459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care laser photocoagulation
Description: standard of care laser photocoagulation
Study NCT04352959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mouthrinse with bêta-cyclodextrin and citrox
Description: 3 daily mouthrinses for 7 days
Study NCT04352959 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: mouthrinse without bêta-cyclodextrin and citrox
Description: 3 daily mouthrinses for 7 days
Study NCT03076203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given orally
Study NCT03076203 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given intravenously
Study NCT00930761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Description: Undergo diffusion-weighted MRI
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion-weighted magnetic resonance imaging
Description: Undergo perfusion-weighted magnetic resonance imaging
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging
Description: Undergo functional MRI
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance spectroscopic imaging
Description: Undergo MR spectroscopic imaging
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic conventional surgery
Description: Undergo maximal surgical resection
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-life assessment
Description: Ancillary studies
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy treatment planning/simulation
Description: Undergo IMRT planning
Study NCT01263821 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Undergo intensity-modulated radiation therapy
Study NCT01263821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Description: Ancillary studies
Study NCT03959332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
Study NCT01826253 — intervention group
Intervention type: DRUG
Intervention: hydroxyethylstarch 130/0.4
Description: Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
Study NCT00397813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study NCT00397813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00397813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00397813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT00397813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo transplantation
Study NCT03848026 — intervention group
Intervention type: OTHER
Intervention: Middle ear fluid viscosity
Description: The patients were subdivided into two groups according to median viscosity level
Study NCT00397813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant
Study NCT00397813 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT02069405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Music
Study NCT02383732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Universal Safety Measures Module (All participants)
Description: During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention \& Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
Study NCT02383732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Universal Safety Measures Module (All participants)
Description: During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention \& Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
Study NCT02383732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proximity Training Module (Bolting Prevention Participants)
Description: During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
Study NCT02383732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Proximity Training Module (Bolting Prevention Participants)
Description: During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
Study NCT02383732 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-In Training Module (Wandering Prevention Participants)
Description: This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
Study NCT02383732 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Check-In Training Module (Wandering Prevention Participants)
Description: This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
Study NCT03007056 — intervention group
Intervention type: OTHER
Intervention: High flow nasal cannula
Description: High flow nasal cannula added to the therapeutic arsenal in neonatal care
Study NCT02854423 — intervention group
Intervention type: DEVICE
Intervention: percutaneous coronary interventions
Description: Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
Study NCT02120014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood volume measurement
Description: Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.~A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream.
Study NCT02120014 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venous plethysmography
Description: venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 20 µg generation 2
Description: Single dose of bimatoprost ophthalmic administered in the study eye on Day 1.
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 15 µg generation 2
Description: Single dose of bimatoprost ophthalmic administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 10 µg generation 2
Description: Single dose of bimatoprost ophthalmic 10 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 6 µg generation 2
Description: Single dose of bimatoprost ophthalmic 6 µg generation 2 administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 15 µg generation 1
Description: Single dose of bimatoprost ophthalmic 15 µg generation 1 administered in the study eye on Day 1.
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 10 µg generation 1
Description: Single dose of bimatoprost ophthalmic 10 µg generation 1 administered in the study eye on Day 1.
Study NCT03848026 — intervention group
Intervention type: OTHER
Intervention: Tympanostomy tube extrusion time
Description: Tympanostomy tube extrusion time of the all patients recorded prospectively.
Study NCT01157364 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bimatoprost 0.03%
Description: One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
Study NCT03991130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2 and Nivolumab
Description: Course length will be 35 days. Subjects will receive 480 mg IV of nivolumab on day 1 of the cycle. The patient will be admitted to UCSD Jacobs Medical center for standard HD IL-2 which will be administered every 8 hrs for up to 14 doses days 8-12 per institutional practice. The patient will be readmitted days 22-28 for HD IL-2 every 8 hrs for up to 14 doses. Nivolumab 480 mg IV will be administered day 35. Scans for response will occur 4 weeks after day 35 nivolumab dose and response will be determined by RECIST 1.1 to determine if the patient will receive the next course.
Study NCT04191382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant (SAR439859)
Description: Pharmaceutical form: Capsules, Route of administration: Oral
Study NCT04191382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Tablets, Route of administration: Oral
Study NCT01717209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: inhaled nitric oxide
Study NCT01717209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Description: inhaled prostacyclin
Study NCT04085679 — intervention group
Intervention type: OTHER
Intervention: Multidisciplinary Mobile Unit (MMU)
Description: MMU is called in case of urgent clinical situations involving patients residing in nursing home
Study NCT03535259 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent sorafenib and IMRT, followed sorafenib maintenance
Description: IMRT 40-60Gy/20-30f; concurrent sorafenib 400mg bid po (it can be given to patients in four weeks before IMRT is applied, so that it can control disease during waiting for IMRT); maintenance sorafenib 400mg bid po until disease progress or unacceptable adverse events; six months is recommended but not mandatory.
Study NCT02941016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab or Alirocumab
Description: All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
Study NCT03679533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Freeze-Dried Cranberry Powder
Description: Freeze-dried cranberry powder (or matched placebo), approximating 500mg active flavonoids per day, taken twice daily for 12 weeks.
Study NCT03679533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo food powder matched for taste, colour, energy and macronutrient content to the active cranberry powder.
Study NCT02631525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
Study NCT02631525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous anesthesia based on propofol
Study NCT03048903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheum Palmatum Root
Description: Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
Study NCT03048903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch Corn
Description: Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
Study NCT02334449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LML134
Description: LML134 will be administered first as single doses and then as multiple doses
Study NCT02334449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: All study cohorts (except food effect cohort) are placebo controlled
Study NCT00492167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-glucan
Study NCT00492167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody 3F8
Study NCT00492167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00492167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis